51 related articles for article (PubMed ID: 15329902)
1. Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.
Sharma S; Mahajan SD; Chevli K; Schwartz SA; Aalinkeel R
Crit Rev Ther Drug Carrier Syst; 2023; 40(4):69-100. PubMed ID: 37075068
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology in Urology.
Jayasimha S
Indian J Urol; 2017; 33(1):13-18. PubMed ID: 28197024
[TBL] [Abstract][Full Text] [Related]
3. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
4. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Han KS; Hong SJ
Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
[TBL] [Abstract][Full Text] [Related]
5. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Han KS; Hong SJ
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
[TBL] [Abstract][Full Text] [Related]
6. Novel epigenetic target therapy for prostate cancer: a preclinical study.
Naldi I; Taranta M; Gherardini L; Pelosi G; Viglione F; Grimaldi S; Pani L; Cinti C
PLoS One; 2014; 9(5):e98101. PubMed ID: 24851905
[TBL] [Abstract][Full Text] [Related]
7. Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.
Tsakalozou E; Eckman AM; Bae Y
Biochem Res Int; 2012; 2012():832059. PubMed ID: 22811914
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology in urology.
Jin S; Labhasetwar V
Urol Clin North Am; 2009 May; 36(2):179-88, viii. PubMed ID: 19406319
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy for prostate cancer].
Rauchenwald M; De Santis M; Fink E; Höltl W; Kramer G; Marei IC; Neumann HJ; Reissigl A; Schmeller N; Stackl W; Hobisch A; Krainer M
Wien Klin Wochenschr; 2008; 120(13-14):440-9. PubMed ID: 18726672
[TBL] [Abstract][Full Text] [Related]
10. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
Nelius T; Klatte T; de Riese W; Filleur S
Int Urol Nephrol; 2008; 40(1):97-104. PubMed ID: 17602304
[TBL] [Abstract][Full Text] [Related]
11. [Research in urologic university clinics. Assessment of current status and perspectives].
Miller K; Krause H
Urologe A; 2006 Sep; 45 Suppl 4():15-9. PubMed ID: 16865381
[No Abstract] [Full Text] [Related]
12. [Therapy of hormone-refractory prostate cancer].
Heidenreich A
Urologe A; 2005 Dec; 44(12):1481-94; quiz 1495. PubMed ID: 16311709
[TBL] [Abstract][Full Text] [Related]
13. [Treatment options for hormone-refractory prostate cancer].
Heidenreich A; Ohlmann CH
Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
17. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
18. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
19. PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.
Meyer JP; Gillatt DA
Prostate Cancer Prostatic Dis; 2002; 5(1):13-5. PubMed ID: 15195124
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
